Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5279780
Max Phase: Preclinical
Molecular Formula: C50H56F4N8O6S2
Molecular Weight: 1005.17
Associated Items:
ID: ALA5279780
Max Phase: Preclinical
Molecular Formula: C50H56F4N8O6S2
Molecular Weight: 1005.17
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCNC(=O)c2ccc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)cc2F)C(C)(C)C)cc1
Standard InChI: InChI=1S/C50H56F4N8O6S2/c1-29-41(70-28-58-29)31-15-13-30(14-16-31)26-57-44(66)39-24-35(63)27-60(39)45(67)42(48(2,3)4)59-40(64)12-10-8-7-9-11-21-56-43(65)36-20-19-34(23-38(36)51)62-47(69)61(46(68)49(62,5)6)33-18-17-32(25-55)37(22-33)50(52,53)54/h13-20,22-23,28,35,39,42,63H,7-12,21,24,26-27H2,1-6H3,(H,56,65)(H,57,66)(H,59,64)/t35-,39+,42-/m1/s1
Standard InChI Key: UNTJCJBQCSZSDR-DCFQOXSYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1005.17 | Molecular Weight (Monoisotopic): 1004.3700 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S.. (2019) Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer., 62 (2): [PMID:30629437] [10.1021/acs.jmedchem.8b01631] |
Source(1):